Effect and Safety of Semaglutide Once-weekly in East Asian Subjects With Overweight or Obesity
Completed Phase 3 NCT03811574
Study Description
This study will look at the change in participants' body weight from the start to the end of the study. This is to compare the effect on body weight in people taking semaglutide (a new medicine) and people taking "dummy" medicine. In addition to taking the medicine, participants will have talks with study staff about healthy food choices, how to be more physically active and what participants can do to lose weight. Participants will either get semaglutide or "dummy" medicine - which treatment participants get is decided by chance. Participants are three times as likely to get semaglutide as "dummy" medicine. Participants will need to take 1 injection once a week. The study medicine is injected with a thin needle in a skinfold in the stomach, thigh or upper arm. The study will last for about one and a half years. Participants will have 14 clinic visits and 11 phone calls with the study doctor.
Study Details
- Registry ID:
- NCT03811574
- Conditions:
- Overweight, Obesity
- Phase:
- Phase 3
- Target Enrollment:
- 401 participants
- Start Date:
- Age Range:
- 18–999 years
- Healthy Volunteers:
- No
Study Locations (20 sites)
-
Novo Nordisk Investigational Site
Toyama-shi, Japan -
Novo Nordisk Investigational Site
Gyeonggi-do, South Korea -
Novo Nordisk Investigational Site
Seoul, South Korea -
Novo Nordisk Investigational Site
Yangsan, South Korea -
Novo Nordisk Investigational Site
Kumamoto, Japan -
Novo Nordisk Investigational Site
Miyazaki, Japan -
Novo Nordisk Investigational Site
Kobe, Japan -
Novo Nordisk Investigational Site
Kashiwara-shi, Japan -
Novo Nordisk Investigational Site
Suita-shi, Japan -
Novo Nordisk Investigational Site
Ibaraki, Japan -
Novo Nordisk Investigational Site
Gunma, Japan -
Novo Nordisk Investigational Site
Chuo-ku, Japan -
Novo Nordisk Investigational Site
Adachi-ku, Japan -
Novo Nordisk Investigational Site
Tokyo, Japan -
Novo Nordisk Investigational Site
Bunkyo-ku, Japan -
Novo Nordisk Investigational Site
Shimotsuke-shi, Japan -
Novo Nordisk Investigational Site
Kanagawa, Japan -
Novo Nordisk Investigational Site
Yamato-shi, Japan -
Novo Nordisk Investigational Site
Sapporo-shi, Japan -
Novo Nordisk Investigational Site
Chitose, Japan
Interested in Participating?
Check your eligibility and learn more about this study on TrialScreen.